Alisertib (MLN8237)

For research use only. Not for use in humans.

目录号：S1133 中文名称：阿利色替

CAS No. 1028486-01-2

Alisertib (MLN8237)是一种选择性Aurora A抑制剂，无细胞试验中IC50为1.2 nM，作用于Aurora A比作用于Aurora B选择性强200倍以上。Alisertib 可诱导细胞周期阻滞、细胞凋亡与自噬。Phase 3。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1375.12	现货
5mg	RMB 983.87	现货
10mg	RMB 1725.78	现货
50mg	RMB 5505.84	现货
200mg	RMB 14496.3	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Alisertib (MLN8237)发表文献235篇：

Cell, 2020, 182(3):685-712.e19

PubMed: 32645325 ( click the link to review the publication )

Nature, 2019, 574(7777):268-272

PubMed: 31578521 ( click the link to review the publication )

Science, 2019, 364(6447)

PubMed: 31249032 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Nat Med, 2016, 22(7):744-53

PubMed: 27213815 ( click the link to review the publication )

Cancer Cell, 2014, 26(3):414-427

PubMed: 25175806 ( click the link to review the publication )

Cell Stem Cell, 2012, 11(2):179-94

PubMed: 22862944 ( click the link to review the publication )

Cancer Commun (Lond), 2021, 10.1002/cac2.12125

PubMed: 33471959 ( click the link to review the publication )

Mol Cell, 2020, 80(6):1104-1122.e9

PubMed: 33259812 ( click the link to review the publication )

J Clin Invest, 2020, 139080

PubMed: 33016928 ( click the link to review the publication )

Nat Commun, 2020, 29;11(1):2086

PubMed: 32350249 ( click the link to review the publication )

Oncogene, 2020, 16

PubMed: 32300176 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9)E2498

PubMed: 32899210 ( click the link to review the publication )

Cancers (Basel), 2020, 12(3)

PubMed: 32235770 ( click the link to review the publication )

Br J Cancer, 2020, 22

PubMed: 32439932 ( click the link to review the publication )

Mol Cancer Ther, 2020, 10.1158/1535-7163.MCT-19-1017

PubMed: 32847978 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(10):3406-3414

PubMed: 33163279 ( click the link to review the publication )

Mol Cancer Res, 2020, 8

PubMed: 32269073 ( click the link to review the publication )

Mol Cancer Res, 2020, molcanres.1226.2019

PubMed: 32591441 ( click the link to review the publication )

Front Oncol, 2020, 10:1354

PubMed: 32974133 ( click the link to review the publication )

J Cell Sci, 2020, 133(24)jcs240267

PubMed: 33376154 ( click the link to review the publication )

Dis Model Mech, 2020, dmm.44289

PubMed: 32571902 ( click the link to review the publication )
J Cell Mol Med, 2020, 10.1111/jcmm.15901

PubMed: 32954665 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(18)E6690

PubMed: 32932728 ( click the link to review the publication )

Sci Adv, 2020, 6(29):eaba1941

PubMed: 32832623 ( click the link to review the publication )

Cancer Res, 2020, 80(16):3424-3435

PubMed: 32595135 ( click the link to review the publication )

J Cancer, 2020, 11(8):2241-2251

PubMed: 32127951 ( click the link to review the publication )

Front Cell Dev Biol, 2020, 8:857

PubMed: 33042987 ( click the link to review the publication )

Cancer Lett, 2020, 491:50-59

PubMed: 32735909 ( click the link to review the publication )

Nucleic Acids Res, 2020, gkaa570

PubMed: 32652013 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2189

PubMed: 31097698 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3485

PubMed: 31375684 ( click the link to review the publication )

Nat Commun, 2019, 10(1):993

PubMed: 30824690 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5566

PubMed: 31804482 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2208

PubMed: 31101817 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(14):4552-4566

PubMed: 30979745 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(11):3430-3442

PubMed: 30755439 ( click the link to review the publication )

Dev Cell, 2019, 50(3):355-366e6

PubMed: 31303441 ( click the link to review the publication )

Cell Syst, 2019, 9(1):74-92.e8

PubMed: 31302152 ( click the link to review the publication )

Cell Syst, 2019, 8(2):163-167

PubMed: 30797774 ( click the link to review the publication )

Cell Rep, 2019, 26(2):293-301e7

PubMed: 30625311 ( click the link to review the publication )

Oncogene, 2019, 38(1):73-87

PubMed: 30082913 ( click the link to review the publication )

EBioMedicine, 2019, 41:120-133

PubMed: 30799199 ( click the link to review the publication )

Cell Death Dis, 2019, 10(12):881

PubMed: 31754113 ( click the link to review the publication )

Cancers (Basel), 2019, 11(2)

PubMed: 30736342 ( click the link to review the publication )

Cell Death Dis, 2019, 10(8):606

PubMed: 31406104 ( click the link to review the publication )
FASEB J, 2019, 33(4):4866-4882

PubMed: 30596512 ( click the link to review the publication )

Cell Chem Biol, 2019, 10.1016/j.chembiol.2019.06.003

PubMed: 31257184 ( click the link to review the publication )

Curr Biol, 2019, 29(21):3563-3578

PubMed: 31668617 ( click the link to review the publication )

PLoS Negl Trop Dis, 2019, 13(5):e0007425

PubMed: 31095613 ( click the link to review the publication )

Antiviral Res, 2019, 170:104572

PubMed: 31376425 ( click the link to review the publication )

Mol Biol Cell, 2019, 30(3):312-323

PubMed: 30485161 ( click the link to review the publication )

Toxicol Sci, 2019, 10.1093/toxsci/kfz123

PubMed: 31132080 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Sci Rep, 2019, 9(1):2211

PubMed: 30778113 ( click the link to review the publication )

Int J Oncol, 2019, 55(4):938-948

PubMed: 31485600 ( click the link to review the publication )

Transl Oncol, 2019, 12(4):683-692

PubMed: 30844579 ( click the link to review the publication )

J Pediatr Hematol Oncol, 2019, 41(6):e359-e370

PubMed: 30702467 ( click the link to review the publication )

Target Oncol, 2019, 14(5):563-575

PubMed: 31429028 ( click the link to review the publication )

Oncotarget, 2019, 10(17):1649-1659

PubMed: 30899434 ( click the link to review the publication )

Oncogene, 2019, 38(40):6696-6710

PubMed: 31391550 ( click the link to review the publication )

Blood Adv, 2019, 3(21):3214-3227

PubMed: 31698452 ( click the link to review the publication )

J Vis Exp, 2019, (151)

PubMed: 31589210 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(8):768-777

PubMed: 29942081 ( click the link to review the publication )

Neuro Oncol, 2018, 20(2):203-214

PubMed: 29016820 ( click the link to review the publication )

Curr Biol, 2018, 28(21):3458-3468e5

PubMed: 30415701 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(24):6594-6610

PubMed: 30181387 ( click the link to review the publication )

Elife, 2018, doi: 107554/eLife38111

PubMed: 30070631 ( click the link to review the publication )

Thyroid, 2018, doi: 101089/thy20180183

PubMed: 30226440 ( click the link to review the publication )

Oncogene, 2018, 37(33):4599-4610

PubMed: 29755130 ( click the link to review the publication )
Oncogene, 2018, 37(22):2921-2935

PubMed: 29515234 ( click the link to review the publication )

Oncogene, 2018, 37(4):502-511

PubMed: 28967900 ( click the link to review the publication )

BMC Biol, 2018, 16(1):116

PubMed: 30336771 ( click the link to review the publication )

Cell Death Dis, 2018, 9(8):781

PubMed: 30013101 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2575-2585

PubMed: 30266802 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2551-2563

PubMed: 30217967 ( click the link to review the publication )

Mol Cell Proteomics, 2018, 17(12):2434-2447

PubMed: 30217950 ( click the link to review the publication )

Mol Pharm, 2018, 15(8):3046-3059

PubMed: 29863884 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(12)

PubMed: 30544932 ( click the link to review the publication )

Apoptosis, 2018, 23(9-10):492-511

PubMed: 30027525 ( click the link to review the publication )

Cell Cycle, 2018, 17(5):652-668

PubMed: 28749250 ( click the link to review the publication )

BMC Cancer, 2018, 18(1):922

PubMed: 30253737 ( click the link to review the publication )

J Cancer, 2018, 9(12):2061-2071

PubMed: 29937924 ( click the link to review the publication )

Cancer Med, 2018, 7(11):5589-5603

PubMed: 30221846 ( click the link to review the publication )

Int J Mol Med, 2018, 41(6):3629-3641

PubMed: 29512701 ( click the link to review the publication )

Pediatr Blood Cancer, 2018, 65(8):e27094

PubMed: 29697184 ( click the link to review the publication )

Mol Med Rep, 2018, 18(1):1206-1210

PubMed: 29845253 ( click the link to review the publication )

Anticancer Res, 2018, 38(6):3471-3476

PubMed: 29848699 ( click the link to review the publication )

Oncotarget, 2018, 9(89):35875-35890

PubMed: 30542505 ( click the link to review the publication )

Oncotarget, 2018, 9(65):32496-32506

PubMed: 30197758 ( click the link to review the publication )

Sci Rep, 2018, 8(1):14017

PubMed: 30228302 ( click the link to review the publication )

Oncotarget, 2018, 9(16):12769-12780

PubMed: 29560108 ( click the link to review the publication )

SLAS Discov, 2018, 23(8):850-861

PubMed: 29742358 ( click the link to review the publication )

J Neurooncol, 2018, 137(3):481-492

PubMed: 29396807 ( click the link to review the publication )
R Soc Open Sci, 2018, 5(12):181303

PubMed: 30662739 ( click the link to review the publication )

Sci Transl Med, 2017, 9(372)

PubMed: 28077684 ( click the link to review the publication )

Mol Cell, 2017, 68(1):210-223e6

PubMed: 28985505 ( click the link to review the publication )

Nat Commun, 2017, 8:14294

PubMed: 28220783 ( click the link to review the publication )

Clin Cancer Res, 2017, 10.1158/1078-0432

PubMed: 28073841 ( click the link to review the publication )

Oncogene, 2017,

PubMed: 27593935 ( click the link to review the publication )

EBioMedicine, 2017, 24:43-55

PubMed: 29030058 ( click the link to review the publication )

Plant Physiol, 2017, 173(1):582-599

PubMed: 27879390 ( click the link to review the publication )

FASEB J, 2017, 32(2):625-638

PubMed: 28970258 ( click the link to review the publication )

Cell Physiol Biochem, 2017, 43(1):94-107

PubMed: 28848145 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1934-1941

PubMed: 28522591 ( click the link to review the publication )

Mol Cancer Ther, 2017,

PubMed: 28615297 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2552-2562

PubMed: 28847989 ( click the link to review the publication )

Eur J Med Chem, 2017, 140:1-19

PubMed: 28918096 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(6):670-682

PubMed: 28235899 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(8):984-997

PubMed: 28442587 ( click the link to review the publication )

J Cell Sci, 2017, 130(4):683-688

PubMed: 28069833 ( click the link to review the publication )

Cell Discov, 2017, 3:16049

PubMed: 28101375 ( click the link to review the publication )

Sci Rep, 2017, 7:45514

PubMed: 28358124 ( click the link to review the publication )

J Biol Chem, 2017, 292(5):1910-1924

PubMed: 28028179 ( click the link to review the publication )

Am J Transl Res, 2017, 9(10):4652-4672

PubMed: 29118925 ( click the link to review the publication )

Am J Transl Res, 2017, 9(3):845-873

PubMed: 28386317 ( click the link to review the publication )

BMC Cell Biol, 2017, 18(1):33

PubMed: 29141582 ( click the link to review the publication )

Curr Cancer Drug Targets, 2017, 17(4):386-401

PubMed: 27396604 ( click the link to review the publication )
Oncotarget, 2017, 8(10):16669-16689

PubMed: 28035071 ( click the link to review the publication )

Oncotarget, 2017, 8(31):50376-50392

PubMed: 28881569 ( click the link to review the publication )

Oncotarget, 2017, 8(19):32117-32133

PubMed: 28389630 ( click the link to review the publication )

Sci Rep, 2017, 7(1):17978

PubMed: 29269934 ( click the link to review the publication )

Sci Rep, 2017, 7:45514

PubMed: 28358124 ( click the link to review the publication )

Oncotarget, 2017, 8(68):112313-112329

PubMed: 29348827 ( click the link to review the publication )

Oncotarget, 2017, 8(12):19738-19759

PubMed: 28160569 ( click the link to review the publication )

Oncotarget, 2017, 8(41):69691-69708

PubMed: 29050234 ( click the link to review the publication )

Oncotarget, 2017, 8(63):107076-107088

PubMed: 29291012 ( click the link to review the publication )

Oncotarget, 2017, 8(59):100326-100338

PubMed: 29245981 ( click the link to review the publication )

Oncotarget, 2017, 8(70):114474-114480

PubMed: 29383095 ( click the link to review the publication )

Oncotarget, 2017, 8(12):19478-19490

PubMed: 28061448 ( click the link to review the publication )

Oncotarget, 2017, 8(54):92926-92942

PubMed: 29190967 ( click the link to review the publication )

Pharmaceuticals (Basel), 2017, 10(3)

PubMed: 29036881 ( click the link to review the publication )

Oncotarget, 2017, 8(31):50376-50392

PubMed: 28881569 ( click the link to review the publication )

Oncotarget, 2017, 8(63):107076-107088

PubMed: 29291012 ( click the link to review the publication )

Oncotarget, 2017, 8(34):57047-57057

PubMed: 28915653 ( click the link to review the publication )

Nat Commun, 2016, 7:10180

PubMed: 26782714 ( click the link to review the publication )

Nat Commun, 2016, 7:11389

PubMed: 27091106 ( click the link to review the publication )

Nat Commun, 2016, 7:12674

PubMed: 27624869 ( click the link to review the publication )

Elife, 2016, 5:e11402

PubMed: 26878753 ( click the link to review the publication )

J Med Chem, 2016, 59(15):7188-211

PubMed: 27391133 ( click the link to review the publication )

Arch Toxicol, 2016, 291(10):4939-54

PubMed: 26404763 ( click the link to review the publication )

Cell Death Dis, 2016, 7:e2135

PubMed: 26962685 ( click the link to review the publication )
Hum Mol Genet, 2016, 25(8):1574-87

PubMed: 26908596 ( click the link to review the publication )

ACS Chem Biol, 2016, 11(12):3400-3411

PubMed: 27768280 ( click the link to review the publication )

Sci Rep, 2016, 6:19567

PubMed: 26777522 ( click the link to review the publication )

J Cell Biochem, 2016, 117(6):1340-51

PubMed: 26529125 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(5):566-76

PubMed: 27082306 ( click the link to review the publication )

Cell Cycle, 2016, 15(3):413-24

PubMed: 26713495 ( click the link to review the publication )

Onco Targets Ther, 2016, 9:3473-84

PubMed: 27366084 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 475(3):251-6

PubMed: 27233613 ( click the link to review the publication )

Exp Hematol, 2016, 44(4):247-56

PubMed: 26724640 ( click the link to review the publication )

Mol Med Rep, 2016, 14(1):394-8

PubMed: 27177156 ( click the link to review the publication )

Biol Bull, 2016, 231(1):61-72

PubMed: 27638695 ( click the link to review the publication )

Oncotarget, 2016, 7(22):33152-64

PubMed: 27121204 ( click the link to review the publication )

Oncotarget, 2016, 7(51):84718-84735

PubMed: 27713168 ( click the link to review the publication )

Oncotarget, 2016, 7(51):84675-84687

PubMed: 27835869 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(2):113-22

PubMed: ( click the link to review the publication )

Nat Cell Biol, 2015, 17(2):113-22

PubMed: 25599390 ( click the link to review the publication )

Nat Commun, 2015, 6:8388

PubMed: 26399523 ( click the link to review the publication )

Mol Cancer, 2015, 14(1):83

PubMed: 25889801 ( click the link to review the publication )

J Invest Dermatol, 2015, 135(9):2292-2300

PubMed: 25848977 ( click the link to review the publication )

J Cell Sci, 2015, 128(2):364-72

PubMed: 25395580 ( click the link to review the publication )

J Cell Sci, 2015, 128(3):527-40

PubMed: 25501809 ( click the link to review the publication )

J Cell Sci, 2015, 128(3):516-26

PubMed: 25501815 ( click the link to review the publication )

J Cell Sci, 2015, 128(20):3769-80

PubMed: 26349807 ( click the link to review the publication )

J Cell Sci, 2015, 128(3):527-40

PubMed: 25501809 ( click the link to review the publication )
J Cell Sci, 2015, 128(2):364-72

PubMed: ( click the link to review the publication )

Int J Mol Sci, 2015,

PubMed: 26729093 ( click the link to review the publication )

Breast Cancer Res Tr, 2015, 149(3):715-26

PubMed: 25667100 ( click the link to review the publication )

Cell Cycle, 2015, 14(24):3908-19

PubMed: 26697841 ( click the link to review the publication )

Drug Des Devel Ther, 2015, 9:1555-84

PubMed: 25792811 ( click the link to review the publication )

Drug Des Devel Ther, 2015, 9:575-601

PubMed: 25632225 ( click the link to review the publication )

BMC Res Notes, 2015, 8:484

PubMed: 26415506 ( click the link to review the publication )

Genes Cancer, 2015, 6(5-6):184-213

PubMed: 26124919 ( click the link to review the publication )

Oncotarget, 2015, 6(34):35247-62

PubMed: 26497213 ( click the link to review the publication )

Clin Cancer Res, 2014, 34(5):2269-74

PubMed: 24778030 ( click the link to review the publication )

Oncogene, 2014, 33(42):4985-96

PubMed: 24166501 ( click the link to review the publication )

Oncogene, 2014, 33(27):3550-60

PubMed: 23955083 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1253

PubMed: 24853431 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1177

PubMed: 24743732 ( click the link to review the publication )

Cell Death Dis, 2014, 6:e1595

PubMed: 25590805 ( click the link to review the publication )

Endocr Relat Cancer, 2014, 21(5):797-811

PubMed: 25074669 ( click the link to review the publication )

Mol Oncol, 2014, 8(8):1419-28

PubMed: 24953013 ( click the link to review the publication )

Epigenetics, 2014, 9(4):611-20

PubMed: 24496381 ( click the link to review the publication )

Mol Cancer Res, 2014, 12(3):433-9

PubMed: 24336958 ( click the link to review the publication )

Biochim Biophys Acta, 2014, 1843(11):2719-2729

PubMed: 25090971 ( click the link to review the publication )

J Transl Med, 2014, 12(1):200

PubMed: 25082261 ( click the link to review the publication )

Mol Carcinog, 2014, 10.1002/mc.22223

PubMed: 25284017 ( click the link to review the publication )

Cell Cycle, 2014, 13(14):2248-61

PubMed: 24875404 ( click the link to review the publication )

FEBS Lett, 2014, 588(14):2198-205

PubMed: 24857377 ( click the link to review the publication )
Chembiochem, 2014, 15(3):443-50

PubMed: 24403173 ( click the link to review the publication )

PLoS One, 2014, 9(12):e113989

PubMed: 25436453 ( click the link to review the publication )

PLoS One, 2014, 9(3):e92402

PubMed: 24642638 ( click the link to review the publication )

PLoS One, 2014, 9(12):e116048

PubMed: 25545367 ( click the link to review the publication )

PLoS One, 2014, 9(7):e101222

PubMed: 24983972 ( click the link to review the publication )

PLoS One, 2014, 9(9):e108758

PubMed: 25268132 ( click the link to review the publication )

PLoS One, 2014, 9(7):e102741

PubMed: 25048812 ( click the link to review the publication )

PLoS One, 2014,

PubMed: ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 452(3):845-51

PubMed: 25218503 ( click the link to review the publication )

Neurosci Lett, 2014, 583:199-204

PubMed: 25263789 ( click the link to review the publication )

J Pediatr Surg, 2014, 49(1):159-65

PubMed: 24439602 ( click the link to review the publication )

Oncotarget, 2014, 5(10):2947-61

PubMed: 24930769 ( click the link to review the publication )

Oncotarget, 2014, 5(15):6229-42

PubMed: 25153724 ( click the link to review the publication )

Oncotarget, 2014, 5(12):4071-86

PubMed: 24901229 ( click the link to review the publication )

Nat Commun, 2013, 4:2656

PubMed: 24141283 ( click the link to review the publication )

EMBO Mol Med, 2013, 5(1):149-66

PubMed: 23180582 ( click the link to review the publication )

Leukemia, 2013, 27(3):560-8

PubMed: 22940834 ( click the link to review the publication )

Cancer Res, 2013, 73(20):6310-22

PubMed: 24067506 ( click the link to review the publication )

EMBO Rep, 2013, 14(9):829-36

PubMed: 23887685 ( click the link to review the publication )

Int J Cancer, 2013, 135(3):751-62

PubMed: 24382688 ( click the link to review the publication )

Oral Oncol, 2013, 49(6):551-9

PubMed: 23481312 ( click the link to review the publication )

ACS Chem Biol, 2013, 8(7):1451-9

PubMed: 23597309 ( click the link to review the publication )

J Cell Sci, 2013, 126(Pt 6):1355-65

PubMed: 23345402 ( click the link to review the publication )

J Cell Sci, 2013, 126(Pt 9):2102-13

PubMed: 23532825 ( click the link to review the publication )
Biochim Biophys Acta, 2013, 1833(10):2220-32

PubMed: 23707954 ( click the link to review the publication )

Epigenetics Chromatin, 2013, 6(1):21

PubMed: 23829974 ( click the link to review the publication )

J Biol Chem, 2013, 289(1):74-88

PubMed: 24273164 ( click the link to review the publication )

Cancer Biol Ther, 2013, 14(5):436-49

PubMed: 23377828 ( click the link to review the publication )

PLoS One, 2013, 8(5):e64306

PubMed: 23717592 ( click the link to review the publication )

PLoS One, 2013, 8(9):e73548

PubMed: 24019927 ( click the link to review the publication )

Oncotarget, 2013,

PubMed: 23328114 ( click the link to review the publication )

J Biol Chem, 2012, 287(33):27670-81

PubMed: 22753416 ( click the link to review the publication )

Breast Cancer Res Tr, 2012, 135(2):433-44

PubMed: 22825030 ( click the link to review the publication )

Cell Cycle, 2012, 11(2):296-309

PubMed: 22214762 ( click the link to review the publication )

Cell Cycle, 2012, 11(13):2567-77

PubMed: 22722494 ( click the link to review the publication )

PLoS One, 2012, 7(2):e30734

PubMed: 22359551 ( click the link to review the publication )

EMBO J, 2011, 30(5):906-19

PubMed: 21297582 ( click the link to review the publication )

Mol Cancer, 2011, 10:131

PubMed: 22011530 ( click the link to review the publication )

Oncotarget, 2011,

PubMed: 21865609 ( click the link to review the publication )

J Cell Biol, 2010, 191(7):1315-32

PubMed: 21187329 ( click the link to review the publication )

EMBO Rep, 2010, 11(12):977-84

PubMed: 21072059 ( click the link to review the publication )

ACS Chem Biol, 2010, 5(6):563-76

PubMed: 20426425 ( click the link to review the publication )

Expert Opin Emerg Dr, 2010, 15(4):615-34

PubMed: 20690888 ( click the link to review the publication )

产品安全说明书

Aurora Kinase抑制剂选择性比较

生物活性

产品描述

特性

MLN8237 是第一个口服有效的小分子Aurora A激酶选择性抑制剂。

靶点

Aurora A ^[1]
(Cell-free assay)

1.2 nM

体外研究

MLN8237作用于Aurora A选择性比作用于结构相关的Aurora B 高200多倍，IC50为396.5 nM, 而对205种其他激酶则没有显著活性。^[1] 0.5 μM MLN8237处理MM1.S和 OPM1 细胞，抑制 Aurora A磷酸化，而不影响 Aurora B调节的组蛋白H3磷酸化。MLN8237作用于多发性骨髓瘤(MM) 细胞系，显著抑制细胞增殖，IC50为0.003-1.71 μM。在BM 基质细胞，IL-6和 IGF-1 存在时，MLN8237作用于原代MM 细胞和MM细胞系，抗增殖活性比只有MLN8237单独作用时高很多。0.5 μM MLN8237 作用于原代MM细胞和细胞系，使G2/M 期细胞提高2到6倍，且显著诱导凋亡和衰老，涉及p53, p21 和p27的上调,及 PARP,caspase 3,和 caspase 9的裂解。此外, MLN8237和 Dexamethasone联用具有协同作用，具有强抗MM 功效, 而和Doxorubicin 及Bortezomib联用则具有另外的功能。^[2] 0.5 μM MLN8237处理 FLO-1, OE19, 和OE33 食管腺癌细胞系，抑制集落形成，且显著提高多倍体细胞百分数,随后提高G1期细胞百分数,而与 Cisplatin (2.5 μM)联用则效果进一步提高，与单独用药相比，诱导产生更多, TAp73β, PUMA, NOXA, cleaved caspase-3, 和cleaved PARP。^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HCT116	NIXJfVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkG5NE42KM7:TR?=	NWPrSHFIPzJiaB?=	MVLEUXNQ	NFXFZ2xKSzVyPUCuNFQh\|ryP	Mn7IQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{[2PFQoRjJ4MUO2Olg1RC:jPh?=
LS174T	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoHHNE42KM7:TR?=	NXzI[npmPzJiaB?=	M1XKRmROW09?	NU\oU5pzUUN3ME2wMlA2KM7:TR?=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF\|Nk[4OEc,OjZzM{[2PFQ9N2F-
T84	NYjjZo1ZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkLHNE42KM7:TR?=	M{C5WVczKGh?	Mki3SG1UVw>?	MXTJR\|UxRTBwMEmg{txO	NGjrRYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzOlY5PCd-Mk[xN\|Y3QDR:L3G+
LS180	NFnocWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnSzNE42KM7:TR?=	MlrEO\|IhcA>?	MVrEUXNQ	MkXsTWM2OD1zIN88US=>	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF\|Nk[4OEc,OjZzM{[2PFQ9N2F-
SW948	NX3xd4FRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYWwMlUh\|ryP	MmOzO\|IhcA>?	NFTKd\|lFVVOR	M1PWcGlEPTB;MTFOwG0>	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF\|Nk[4OEc,OjZzM{[2PFQ9N2F-
HCT15	M1q1SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV;tO5NNOC53IN88US=>	M1PxcVczKGh?	NH2zWXlFVVOR	MlLJTWM2ODxyLkSg{txO	NEXwNoQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzOlY5PCd-Mk[xN\|Y3QDR:L3G+
DLD-1	MlXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEPwdmUxNjVizszN	NHjURmY4OiCq	M2W4UmROW09?	MV\JR\|UxRDBwODFOwG0>	NHSwfJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzOlY5PCd-Mk[xN\|Y3QDR:L3G+
MIP-101	NF\1dFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUThO3RCOC53IN88US=>	NFy3N444OiCq	NIC1ZZFFVVOR	M4fifGlEPTB;MTFOwG0>	M4jLdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUO2Olg1Lz5{NkGzOlY5PDxxYU6=
SNU1544	NHziS4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1vZUlAvPSEQvF2=	NGrCfGw4OiCq	Mn20SG1UVw>?	Ml3yTWM2OD1zIN88US=>	M1rQNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUO2Olg1Lz5{NkGzOlY5PDxxYU6=
OCI-Ly10	M2ruTWN6fG:2b4jpZ{BCe3OjeR?=		MXK3NkBp	M1\hWWROW09?	NWXlPWZ7UUN3ME2wMlA2QCEQvF2=	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh5OEOzNUc,OjV6N{izN\|E9N2F-
SU-DHL2	MXPDfZRwfG:6aXOgRZN{[Xl?		MnrFO\|IhcA>?	Mk\QSG1UVw>?	MVrJR\|UxRTBwMEGg{txO	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh5OEOzNUc,OjV6N{izN\|E9N2F-
OCI-LY7	MVPDfZRwfG:6aXOgRZN{[Xl?		M4XqSFczKGh?	MlTPSG1UVw>?	NXyyenRQUUN3ME2wMlA5OSEQvF2=	M1;E[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEe4N\|MyLz5{NUi3PFM{OTxxYU6=
SU-DHL6	MlrsR5l1d3SxeHnjJGF{e2G7		NFjmZYw4OiCq	MVrEUXNQ	MXTJR\|UxRTBwNEiyJO69VQ>?	M4jmOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEe4N\|MyLz5{NUi3PFM{OTxxYU6=
Jeko-1	NXqxdVVPS3m2b4TvfIlkKEG\|c3H5		MVq3NkBp	NFnPOYhFVVOR	NISz[2JKSzVyPUCuNFI6KM7:TR?=	NX\KNmdERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4O\|g{OzFpPkK1PFc5OzNzPD;hQi=>
JVM-2	NX35[IUzS3m2b4TvfIlkKEG\|c3H5		NXHDU2NzPzJiaB?=	NXfVWGFqTE2VTx?=	NVO1eYJyUUN3ME2wMlAyKM7:TR?=	NUnmTXF1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4O\|g{OzFpPkK1PFc5OzNzPD;hQi=>
Rec-1	NHfENW9EgXSxdH;4bYMhSXO\|YYm=		M1j3SVczKGh?	NXnJe\|R5TE2VTx?=	MWDJR\|UxRTBwMEi3JO69VQ>?	M{TsblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEe4N\|MyLz5{NUi3PFM{OTxxYU6=
Z-138	NX7semUzS3m2b4TvfIlkKEG\|c3H5		MUG3NkBp	MX3EUXNQ	NHviOGxKSzVyPUCuNFE{KM7:TR?=	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh5OEOzNUc,OjV6N{izN\|E9N2F-
H9	MUXDfZRwfG:6aXOgRZN{[Xl?		NF\oTYU4OiCq	NIjqNGRFVVOR	NFLXWldKSzVyPUCuOkDPxE1?	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh5OEOzNUc,OjV6N{izN\|E9N2F-
HH	NWDmc3Z{S3m2b4TvfIlkKEG\|c3H5		M3\4V\|czKGh?	MoK3SG1UVw>?	M{T1fWlEPTB;MD63JO69VQ>?	NULkR4dxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4O\|g{OzFpPkK1PFc5OzNzPD;hQi=>
DND41	Mk\JR5l1d3SxeHnjJGF{e2G7		MmflO\|IhcA>?	MonQSG1UVw>?	NWXlZY1MUUN3ME2wMlEh\|ryP	NF3rW2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi3PFM{OSd-MkW4O\|g{OzF:L3G+
CCL119	NYDFU4tUS3m2b4TvfIlkKEG\|c3H5		MYG3NkBp	NGLPdJFFVVOR	MWPJR\|UxRTBwME[yJO69VQ>?	M4XyTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEe4N\|MyLz5{NUi3PFM{OTxxYU6=
J.Cam 1.6	MmXRR5l1d3SxeHnjJGF{e2G7		M1nrSlczKGh?	MmT6SG1UVw>?	MWXJR\|UxRTBwMUC1JO69VQ>?	MnLxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6N{izN\|EoRjJ3OEe4N\|MyRC:jPh?=
Sup-T1	MXLDfZRwfG:6aXOgRZN{[Xl?		MXK3NkBp	NXLueW5iTE2VTx?=	NYDMTpVbUUN3ME2yMlE1OiEQvF2=	NIjhTZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi3PFM{OSd-MkW4O\|g{OzF:L3G+
Tib 152	MXLDfZRwfG:6aXOgRZN{[Xl?		M1GyWlczKGh?	MlG4SG1UVw>?	MWrJR\|UxRTBwODFOwG0>	M3ruPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEe4N\|MyLz5{NUi3PFM{OTxxYU6=
MCF7	M{mzOWZ2dmO2aX;uJGF{e2G7	NGDoVYU2KM7:TR?=	NH7sO3AzPCCq	NI\6[IhFVVOR	NYXLPVRzUW6mdXPld{BIOi:PIHHydoV{fA>?	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh\|NESwNUc,OjV6M{S0NFE9N2F-
MDA-MB-231	MlvsSpVv[3Srb36gRZN{[Xl?	M3\ZPFUh\|ryP	NH;hOGQzPCCq	MUjEUXNQ	NEH5bG5KdmS3Y3XzJGc{N01iYYLy[ZN1	NHv0bmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUizOFQxOSd-MkW4N\|Q1ODF:L3G+
MCF7	NXP4WGRGTnWwY4Tpc44hSXO\|YYm=	NX3CeG9UPSEQvF2=	MofSNlQhcA>?	MVXEUXNQ	NVyxRpdDTGWlcnXhd4V{KHSqZTDlfJBz\XO\|aX;uJIxmfmWuIH;mJGNFUzFxQ1TDNi=>	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh\|NESwNUc,OjV6M{S0NFE9N2F-
MCF7	MXPGeY5kfGmxbjDBd5NigQ>?	NWHL[pBuPSEQvF2=	NFexVpAzPCCq	NY\Fb\|BQTE2VTx?=	M1PrSWRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDDSGsz	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh\|NESwNUc,OjV6M{S0NFE9N2F-
MCF7	NIX0S45HfW6ldHnvckBCe3OjeR?=	MUi1JO69VQ>?	NUn4W\|REOjRiaB?=	Mo\KSG1UVw>?	MVTE[YNz\WG\|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZiY4njcIlvKEJz	M2LGVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEO0OFAyLz5{NUizOFQxOTxxYU6=
MCF7	NUjXVpQxTnWwY4Tpc44hSXO\|YYm=	NH;wXWU2KM7:TR?=	M4D6ZVI1KGh?	M1XGVWROW09?	M3vQdGlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDwNlEhX2GoMT;DbZAy	Ml3YQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6M{S0NFEoRjJ3OEO0OFAyRC:jPh?=
MCF7	NVfmSnBkTnWwY4Tpc44hSXO\|YYm=	NEPrUY42KM7:TR?=	NUDlXVZxOjRiaB?=	NF32dXVFVVOR	MV7JcoNz\WG\|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZicEK3JGtqeDF?	NWn4TZRlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4N\|Q1ODFpPkK1PFM1PDBzPD;hQi=>
MDA-MB-231	Mnj2SpVv[3Srb36gRZN{[Xl?	MWe1JO69VQ>?	NX\4b4E6OjRiaB?=	NX7IUpRXTE2VTx?=	MVfE[YNz\WG\|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZiQ1TLNU9ETEN{	NHjpb\|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUizOFQxOSd-MkW4N\|Q1ODF:L3G+
MDA-MB-231	MWHGeY5kfGmxbjDBd5NigQ>?	MWqxJO69VQ>?	NXfue2hxOjRiaB?=	M{TXN2ROW09?	MkXFTY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIFPET\|I>	NVPUS5p3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4N\|Q1ODFpPkK1PFM1PDBzPD;hQi=>
MDA-MB-231	MY\GeY5kfGmxbjDBd5NigQ>?	NHn6WYU2KM7:TR?=	M1S2UlI1KGh?	NYfvNlRJTE2VTx?=	M3TQNGRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDjfYNtcW5iQkG=	M1zmTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEO0OFAyLz5{NUizOFQxOTxxYU6=
MDA-MB-231	MmWzSpVv[3Srb36gRZN{[Xl?	M3zWS\|Uh\|ryP	MoLmNlQhcA>?	NUDSWnJQTE2VTx?=	M{LzSmlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDwNlEhX2GoMT;DbZAy	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh\|NESwNUc,OjV6M{S0NFE9N2F-
MDA-MB-231	MUPGeY5kfGmxbjDBd5NigQ>?	NEHLT\|Y2KM7:TR?=	NWDqV4JMOjRiaB?=	NIrEO3VFVVOR	NHfzO\|hKdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gdFI4KEurcEG=	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh\|NESwNUc,OjV6M{S0NFE9N2F-
MDA-MB-231	M1nMZ2Z2dmO2aX;uJGF{e2G7	NIjLN2g2KM7:TR?=	NIP5cHczPCCq	MnPmSG1UVw>?	Moq2TY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIIC1Ny=>	NXjnc\|N[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4N\|Q1ODFpPkK1PFM1PDBzPD;hQi=>
MCF7	NGWzUINCeG:ydH;zbZMhSXO\|YYm=	MnvyOUDPxE1?	NEjL[\|kzPCCq	NH7GV21FVVOR	Ml;WTY5lfWOnczDhdI9xfG:2aXOg[IVifGh?	M1O3eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEO0OFAyLz5{NUizOFQxOTxxYU6=
MDA-MB-231	NFnFZplCeG:ydH;zbZMhSXO\|YYm=	MUC1JO69VQ>?	M2XqTlI1KGh?	MWDEUXNQ	NEfmPJFKdmS3Y3XzJIFxd3C2b4TpZ{Bl\WG2aB?=	NHftVVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUizOFQxOSd-MkW4N\|Q1ODF:L3G+
MCF7	NVrZdJBoTnWwY4Tpc44hSXO\|YYm=	NUn5XVJoOSEQvF2=	NEWzPYI4OiCq	NFz6R\|ZFVVOR	NXjOXIREUW6mdXPld{BifXSxcHjh[4lkKGSnYYTo	NHrKeVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUizOFQxOSd-MkW4N\|Q1ODF:L3G+
MDA-MB-231	MmGzSpVv[3Srb36gRZN{[Xl?	NIHOXoQyKM7:TR?=	NWXrfIlPPzJiaB?=	NHraWmVFVVOR	NHywT\|VKdmS3Y3XzJIF2fG:yaHHnbYMh\GWjdHi=	NGjRfoY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUizOFQxOSd-MkW4N\|Q1ODF:L3G+
U-2 OS	MnjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWO1NEDPxE1?	MYGyOEBp	M3f6fmROW09?	MlfaTWM2OD1zNj62JO69VQ>?	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd7MkixNUc,OjV5OUK4NVE9N2F-
MG-63	MoTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXTPSZh[PTBizszN	MYKyOEBp	M12zO2ROW09?	NGLaW25KSzVyPUmuOUDPxE1?	NGjtfWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe5NlgyOSd-MkW3PVI5OTF:L3G+
U-2 OS	MlPVRZBweHSxc3nzJGF{e2G7	M3fseFUh\|ryP	NFnPPFczPCCq	M2\Zb2ROW09?	MkX6TY5lfWOnczDhdI9xfG:2aXOgZ4VtdCCmZXH0bC=>	MlPzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5OUK4NVEoRjJ3N{myPFEyRC:jPh?=
MG-63	M4e2e2Fxd3C2b4Ppd{BCe3OjeR?=	NYLJNHN5PSEQvF2=	NWrLfm5pOjRiaB?=	Mm[xSG1UVw>?	NWL3UFBVUW6mdXPld{BieG:ydH;0bYMh[2WubDDk[YF1cA>?	NI\GXoc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe5NlgyOSd-MkW3PVI5OTF:L3G+
U-2 OS	NHW0PG5HfW6ldHnvckBCe3OjeR?=	NVPlUmM1PSEQvF2=	NULwfHd6OjRiaB?=	M3i0ZmROW09?	MkPPVJJwdW:2ZYOgZZV1d3CqYXfpZ{Bk\WyuIHTlZZRp	NF[3UIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe5NlgyOSd-MkW3PVI5OTF:L3G+
MG-63	NEjKTllHfW6ldHnvckBCe3OjeR?=	NFX0SpI2KM7:TR?=	Mm[0NlQhcA>?	Ml62SG1UVw>?	MUjQdo9ud3SnczDheZRweGijZ3njJINmdGxiZHXheIg>	M{Lq[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{myPFEyLz5{NUe5NlgyOTxxYU6=
PANC-1	M1fLRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlPXOVAh\|ryP	Mn3vNlQhcA>?	MXTEUXNQ	NVrEdHQzUUN3ME23MlEh\|ryP	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ\|MkKyOUc,OjV4M{KyNlU9N2F-
BxPC-3	M3nzUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWm1NEDPxE1?	NFLPdJczPCCq	NUjPfYNzTE2VTx?=	M1TvR2lEPTB;Nj64JO69VQ>?	M{e5UlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkOyNlI2Lz5{NU[zNlIzPTxxYU6=
PANC-1	MXXGeY5kfGmxbjDBd5NigQ>?	Mn\LOUDPxE1?	MV[yOEBp	M3\BZWROW09?	M3zLfWlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgbY4hTzJxTTDwbIF{\Q>?	M{n2cVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkOyNlI2Lz5{NU[zNlIzPTxxYU6=
BxPC-3	NYfPdodRTnWwY4Tpc44hSXO\|YYm=	M2i1eVUh\|ryP	NU\4SJNHOjRiaB?=	NEe4OYVFVVOR	MorETY5lfWOnczDj[YxtKGO7Y3zlJIFzemW\|dDDpckBIOi:PIIDoZZNm	M3ywd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkOyNlI2Lz5{NU[zNlIzPTxxYU6=
PANC-1	MYTGeY5kfGmxbjDBd5NigQ>?	MXW1JO69VQ>?	NVTjT4tXOjRiaB?=	NWP3O4x4TE2VTx?=	M4nkSGlv\HWlZYOgZZV1d3CqYXfpZ{Bk\WyuIHTlZZRp	NIPMN5U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[zNlIzPSd-MkW2N\|IzOjV:L3G+
BxPC-3	NWT5T3ZHTnWwY4Tpc44hSXO\|YYm=	M3nrO\|Uh\|ryP	MnzQNlQhcA>?	NEjIRXhFVVOR	M3rSbWlv\HWlZYOgZZV1d3CqYXfpZ{Bk\WyuIHTlZZRp	M2jKdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkOyNlI2Lz5{NU[zNlIzPTxxYU6=
SKOV3	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWLSV\|d4OTByIN88US=>	NXj4UpRwOjRiaB?=	MnjXSG1UVw>?	NH;UZ\|VKSzVyPUKwMlQ5KM7:TR?=	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ{NEe1NEc,OjV4MkS3OVA9N2F-
OVCAR4	NFTkO4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYnSXZNjOTByIN88US=>	Mn76NlQhcA>?	Ml62SG1UVw>?	MUDJR\|UxRTJ{LkGzJO69VQ>?	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ{NEe1NEc,OjV4MkS3OVA9N2F-
SKOV3	NVL1SFJ7TnWwY4Tpc44hSXO\|YYm=	M3TFRVUh\|ryP	NVzFXnVGPzJiaB?=	NV\IVoVZTE2VTx?=	NFrTUYNKdmS3Y3XzJGczN01iYYLy[ZN1	NX[5UFZDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2NlQ4PTBpPkK1OlI1PzVyPD;hQi=>
OVCAR4	M3e5TWZ2dmO2aX;uJGF{e2G7	MnmzOUDPxE1?	MXy3NkBp	NX3qS2c6TE2VTx?=	Ml\rTY5lfWOnczDHNk9OKGG{cnXzeC=>	NIfQPZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[yOFc2OCd-MkW2NlQ4PTB:L3G+
SKOV3	M4jLPWFxd3C2b4Ppd{BCe3OjeR?=	NETLWHU2KM7:TR?=	NHSwTpozPCCq	NVnNWmZlTE2VTx?=	MXTJcoR2[2W\|IHHwc5B1d3Orcx?=	M4HoeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkK0O\|UxLz5{NU[yOFc2ODxxYU6=
OVCAR4	MYjBdI9xfG:\|aYOgRZN{[Xl?	MWe1JO69VQ>?	Mlz4NlQhcA>?	Ml\nSG1UVw>?	NXG2e3NvUW6mdXPld{BieG:ydH;zbZM>	NYHXN4hFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2NlQ4PTBpPkK1OlI1PzVyPD;hQi=>
AGS	M1qwXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUT5XpN7OjVizszN	MV[yOEBp	MXvEUXNQ	MmDRTWM2OD1zOT6wPUDPxE1?	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZyOUmyN{c,OjV4MEm5NlM9N2F-
NCI-N78	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYiyOUDPxE1?	Mn2zNlQhcA>?	NEDz[m1FVVOR	NUf0V4VFUUN3ME2yOk4{OyEQvF2=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZyOUmyN{c,OjV4MEm5NlM9N2F-
AGS	M1z2fmFxd3C2b4Ppd{BCe3OjeR?=	MUm1JO69VQ>?	MX[yOEBp	MVPEUXNQ	MY\JcoR2[2W\|IHHwc5B1d3Orcx?=	NEftbFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[wPVkzOyd-MkW2NFk6OjN:L3G+
NCI-N78	NXroNYJXSXCxcITvd4l{KEG\|c3H5	Mn;OOUDPxE1?	MlLiNlQhcA>?	M2XqOWROW09?	MWrJcoR2[2W\|IHHwc5B1d3Orcx?=	NUXXbVhWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2NFk6OjNpPkK1OlA6QTJ\|PD;hQi=>
AGS	MU\GeY5kfGmxbjDBd5NigQ>?	M1TNTVUh\|ryP	M2rue\|I1KGh?	NFPkSmZFVVOR	MnPVTY5lfWOnczD0bIUh[XW2b4DoZYd6	MmHJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4MEm5NlMoRjJ3NkC5PVI{RC:jPh?=
NCI-N78	MXTGeY5kfGmxbjDBd5NigQ>?	NWrUUYs{PSEQvF2=	M1\nOFI1KGh?	NFXVOGpFVVOR	M4LGUGlv\HWlZYOgeIhmKGG3dH;wbIFogQ>?	NF7Fe3k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[wPVkzOyd-MkW2NFk6OjN:L3G+
HSC-3	NIq0bWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1iyfVEh\|ryP	MoS5OFghcA>?		NG\Ic2lKSzVyPUCuOVQh\|ryP	NYHmVXpqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzOlYyPDNpPkK1N\|Y3OTR\|PD;hQi=>
GB30	NF\LXldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2[0SlEh\|ryP	MnG1O{Bl	MX\EUXNQ	NVfmVJk2UUN3ME2wMlAyOSEQvF2=	MoXHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzME[0NlgoRjJ3MUC2OFI5RC:jPh?=
GB9	NHzFVIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH\ueJAyKM7:TR?=	MV63JIQ>	NX\KXG5rTE2VTx?=	NXrlbopFUUN3ME2wMlAzPCEQvF2=	Mmf0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzME[0NlgoRjJ3MUC2OFI5RC:jPh?=
GB169	NHjPXG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYX3N4tmOSEQvF2=	Mm\XO{Bl	MYrEUXNQ	MV\JR\|UxRTBwMEOyJO69VQ>?	Ml\MQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzME[0NlgoRjJ3MUC2OFI5RC:jPh?=
T24	MXnGeY5kfGmxbjDBd5NigQ>?	NX\2UFg4OSEQvF2=	M3fzR\|Q5KGh?	NIfYeJBFVVOR	MWnJcoR2[2W\|IHPlcIwh[3mlbHWgZZJz\XO2	NHXK[ZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{SwN\|Y{Oyd-MkO0NFM3OzN:L3G+
RT4	MYTGeY5kfGmxbjDBd5NigQ>?	NFq4c3oyKM7:TR?=	M1zBe\|Q5KGh?	M{P6PWROW09?	NET3NHVKdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzRyM{[zN{c,OjN2MEO2N\|M9N2F-
UM-UC-3	M1;DemZ2dmO2aX;uJGF{e2G7	MXSxJO69VQ>?	Mnv6OFghcA>?	NHvHRmxFVVOR	MUDJcoR2[2W\|IHPlcIwh[3mlbHWgZZJz\XO2	MnfLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2MEO2N\|MoRjJ\|NECzOlM{RC:jPh?=
T24	NWXjfGV5SXCxcITvd4l{KEG\|c3H5	MoXTN{4yPiEQvF2=	MonHPVYhcA>?	M2n5TmROW09?	NIex[3RKSzVyPUCuNFMxPiEQvF2=	NUP4ZnBIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0NFM3OzNpPkKzOFA{PjN\|PD;hQi=>
RT4	MV3BdI9xfG:\|aYOgRZN{[Xl?	Ml;DN{4yPiEQvF2=	MlrLPVYhcA>?	MUPEUXNQ	MmW5TWM2OD1yLkGxPVgh\|ryP	M3Tl[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NECzOlM{Lz5{M{SwN\|Y{OzxxYU6=
UM-UC-3	NGX2ephCeG:ydH;zbZMhSXO\|YYm=	MmLEN{4yPiEQvF2=	NH3EN3o6PiCq	MWfEUXNQ	NETG[41KSzVyPUCuNFQ1QSEQvF2=	NVm0UG5wRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0NFM3OzNpPkKzOFA{PjN\|PD;hQi=>
OVCAR-5	M2LUbmZ2dmO2aX;uJGF{e2G7	MUW1NEBvVQ>?			MVHJcohq[mm2czDj[YxtKG2rZ4LheIlwdg>?	NWrIbFU5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzN\|Q{OjdpPkKzN\|M1OzJ5PD;hQi=>
SKOV3ip2	M1XJO2Z2dmO2aX;uJGF{e2G7	M4i2[\|UxKG6P			M{nHWWlvcGmkaYTzJINmdGxibXnndoF1cW:w	MkLsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|M{SzNlcoRjJ\|M{O0N\|I4RC:jPh?=
S462	NF7lVm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUKxNFAh\|ryP	MUe3NkBp	NUHvT4pETE2VTx?=	NH7ZephCfHSnboXheIV{KGOnbHyg[5Jwf3Sq	MnrMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MkixNVQoRjJ\|M{K4NVE1RC:jPh?=
2884	M2LiOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4TXT\|ExOCEQvF2=	NGLGU4I4OiCq	MnfCSG1UVw>?	M{\0O2F1fGWwdXH0[ZMh[2WubDDndo94fGh?	M1LM[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{K4NVE1Lz5{M{OyPFEyPDxxYU6=
2885	MmjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml;ONVAxKM7:TR?=	NWPDUnlTPzJiaB?=	Ml;wSG1UVw>?	M3\yemF1fGWwdXH0[ZMh[2WubDDndo94fGh?	M3W3elxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{K4NVE1Lz5{M{OyPFEyPDxxYU6=
CRL-2396	MnTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVHTN5p2OTByIN88US=>		Mmn4e4F1\XJ?	NUnDPG1lUUN3ME2wMlA6OiEQvF2=	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzF3M{WyOEc,OjNzNUO1NlQ9N2F-
TIB-48	MofqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoPyNVAxKM7:TR?=		M4rS[5difGW{	NFj5XHNKSzVyPUCuNFg5KM7:TR?=	NVjOUYFVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOxOVM2OjRpPkKzNVU{PTJ2PD;hQi=>
CRL-2396	NH7kenNEgXSxdH;4bYMhSXO\|YYm=	NVy4R\|d5OSEQvF2=	M4n5VFQ5KGh?	MW\3ZZRmeg>?	NHLqT3hKdmS3Y3XzJIFxd3C2b4Ppdy=>	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzF3M{WyOEc,OjNzNUO1NlQ9N2F-
TIB-48	NETzWo9EgXSxdH;4bYMhSXO\|YYm=	NHfiVHcyKM7:TR?=	MmLoOFghcA>?	MVX3ZZRmeg>?	M{nvUmlv\HWlZYOgZZBweHSxc3nz	NVjDVo1ORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOxOVM2OjRpPkKzNVU{PTJ2PD;hQi=>
AGS	NILrXYVEgXSxdH;4bYMhSXO\|YYm=	MVGwMlUh\|ryP	M1u1PVI1KGh?	MUDEUXNQ	M1nzOGRm[3KnYYPld{Bk\WyuIIP1dpZqfmGu	NILQRlg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mkm3NlYyOSd-MkK5O\|I3OTF:L3G+
FLO-1	NWrqXGQ5S3m2b4TvfIlkKEG\|c3H5	Mn\BNE42KM7:TR?=	MXuyOEBp	NGLGNYdFVVOR	MmTsSIVkemWjc3XzJINmdGxic4Xyeol3[Wx?	MmD1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ7N{K2NVEoRjJ{OUeyOlEyRC:jPh?=
OE33	NF3RSolEgXSxdH;4bYMhSXO\|YYm=	MWiwMlUh\|ryP	Mk\LNlQhcA>?	NHXMSlJFVVOR	NY\LVlFTTGWlcnXhd4V{KGOnbHygd5Vzfmm4YXy=	MlrtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ7N{K2NVEoRjJ{OUeyOlEyRC:jPh?=
SKLMS	MYfDfZRwfG:6aXOgRZN{[Xl?	MYS3OUBvVQ>?	NInKPI06PiCq		NVO4SYdqUW6mdXPld{BieG:ydH;zbZM>	M2TTblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OEKxPVk4Lz5{MkiyNVk6PzxxYU6=
Leio285	NUPuZXVrS3m2b4TvfIlkKEG\|c3H5	Ml7pO\|Uhdk1?	NXLNUpBuQTZiaB?=		M2TwU2lv\HWlZYOgZZBweHSxc3nz	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh{MUm5O{c,OjJ6MkG5PVc9N2F-
Mes-Sa	NWfvcoV5S3m2b4TvfIlkKEG\|c3H5	MWK3OUBvVQ>?	MnHIPVYhcA>?		NVvVSVNSUW6mdXPld{BieG:ydH;zbZM>	MoryQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6MkG5PVcoRjJ{OEKxPVk4RC:jPh?=
DAOY	M2LhPWN6fG:2b4jpZ{BCe3OjeR?=	NX7sb4w1OTBizszN	NIjHO\|c4OiCq	NX\ISlAxTE2VTx?=	NYLNPHIxUUN3ME2wMlA1KM7:TR?=	NHPIUW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mk[2PVM{PSd-MkK2Olk{OzV:L3G+
IMR32	MWTDfZRwfG:6aXOgRZN{[Xl?	M3LkdVExKM7:TR?=	MWq3NkBp	MmnzSG1UVw>?	M2O5OmlEPTB;MD6wN{DPxE1?	NXnqWJc{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK2Olk{OzVpPkKyOlY6OzN3PD;hQi=>
Molt-4	NWD0[oZ6S3m2b4TvfIlkKEG\|c3H5	M4\1d\|ExKM7:TR?=	NEG2PFk4OiCq	NISzTGNFVVOR	NX3OO2tyUUN3ME2wMlAzKM7:TR?=	MlnxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ4NkmzN\|UoRjJ{Nk[5N\|M2RC:jPh?=
MOLM-13	M33KV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWfvbmk4OyEQvF2=	MmLnO\|IhcA>?		NEjTPYZFcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5	NF7IZ2w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkS4PFI1QSd-MkK0PFgzPDl:L3G+
HL-60	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2HrNFMh\|ryP	M2DDeVczKGh?		NY\BToZZTGmvaX7pd4hmeyClZXzsJJZq[WKrbHn0fS=>	NI[3OHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkS4PFI1QSd-MkK0PFgzPDl:L3G+
MV4-11	M2\uOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUHtTXJlOyEQvF2=	M1rpRVczKGh?		M{DwRWRqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm=	MnnVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2OEiyOFkoRjJ{NEi4NlQ6RC:jPh?=
SKM-1	M{noOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEj4bGI{KM7:TR?=	MV23NkBp		M{PDfmRqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm=	NVTydpV1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0PFgzPDlpPkKyOFg5OjR7PD;hQi=>
SH2	Mn3NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1;6NVMh\|ryP	MUO3NkBp		NWTMcFF3TGmvaX7pd4hmeyClZXzsJJZq[WKrbHn0fS=>	M1r5W\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NEi4NlQ6Lz5{MkS4PFI1QTxxYU6=
NOMO-1	MljZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWfoSVZJOyEQvF2=	NE\sSZA4OiCq		M4nxPWRqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm=	MnG1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2OEiyOFkoRjJ{NEi4NlQ6RC:jPh?=
OCL-AML2	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVizJO69VQ>?	M2TIZ\|czKGh?		NXnlTHJJTGmvaX7pd4hmeyClZXzsJJZq[WKrbHn0fS=>	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjR6OEK0PUc,OjJ2OEiyOFk9N2F-
PL-21	NFTYZWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX63[5lQOyEQvF2=	NVfKdlR4PzJiaB?=		NVvFbnQzTGmvaX7pd4hmeyClZXzsJJZq[WKrbHn0fS=>	NFPDXGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkS4PFI1QSd-MkK0PFgzPDl:L3G+
KG-1	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{HwPFMh\|ryP	M{nkN\|czKGh?		NXvRfJNZTGmvaX7pd4hmeyClZXzsJJZq[WKrbHn0fS=>	NF\2UVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkS4PFI1QSd-MkK0PFgzPDl:L3G+
A172	M3zndWN6fG:2b4jpZ{BCe3OjeR?=	MWSxNFAh\|ryP	MX6yOEBp	M3OzPWROW09?	MVvJR\|UxRTBwMUKwJO69VQ>?	NELxNpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkK3OFM6QSd-MkKyO\|Q{QTl:L3G+
U87	MV\DfZRwfG:6aXOgRZN{[Xl?	MnzFNVAxKM7:TR?=	NFOwSHczPCCq	NEO4TnhFVVOR	NHjqUmdKSzVyPUCuNVA2KM7:TR?=	M4G1OlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{Mke0N\|k6Lz5{MkK3OFM6QTxxYU6=
U251	NFfV[mJEgXSxdH;4bYMhSXO\|YYm=	NXH2S5FSOTByIN88US=>	M{jFb\|I1KGh?	NV3Ye5FsTE2VTx?=	MnPTTWM2OD1yLkGwNEDPxE1?	NUC1ZWNCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyO\|Q{QTlpPkKyNlc1Ozl7PD;hQi=>
T98	NV3ieWtzS3m2b4TvfIlkKEG\|c3H5	NW\XdJp7OTByIN88US=>	MX[yOEBp	NHnOeIJFVVOR	Mlz2TWM2OD1yLkGyOUDPxE1?	NVTHWm1MRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyO\|Q{QTlpPkKyNlc1Ozl7PD;hQi=>
LN18	MkXsR5l1d3SxeHnjJGF{e2G7	NUjZNVJiOTByIN88US=>	MkDoNlQhcA>?	MXnEUXNQ	NFvBdXZKSzVyPUCuNlExKM7:TR?=	M1HsclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{Mke0N\|k6Lz5{MkK3OFM6QTxxYU6=
LN443	MYrDfZRwfG:6aXOgRZN{[Xl?	NHvCN4MyODBizszN	NH2wflEzPCCq	NYSyN45jTE2VTx?=	NXHHWWw6UUN3ME2wMlIzOCEQvF2=	NYO5SXRORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyO\|Q{QTlpPkKyNlc1Ozl7PD;hQi=>
HF66	M{m4VGN6fG:2b4jpZ{BCe3OjeR?=	M2[2OlExOCEQvF2=	MUKyOEBp	MljSSG1UVw>?	M4L3V2lEPTB;MD6yNlUh\|ryP	MoLkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{N{SzPVkoRjJ{Mke0N\|k6RC:jPh?=
HF2303	NYnQN2FnS3m2b4TvfIlkKEG\|c3H5	MV[xNFAh\|ryP	M2jsW\|I1KGh?	NHLBUIVFVVOR	NGLaV2dKSzVyPUCuNFYxKM7:TR?=	MkLoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{N{SzPVkoRjJ{Mke0N\|k6RC:jPh?=
HF2359	NXn3XlFIS3m2b4TvfIlkKEG\|c3H5	M133R\|ExOCEQvF2=	NGi0dowzPCCq	M1XHV2ROW09?	MX;JR\|UxRTBwME[wJO69VQ>?	NH7ZcWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkK3OFM6QSd-MkKyO\|Q{QTl:L3G+
HF2414	NF\PbIJEgXSxdH;4bYMhSXO\|YYm=	Mon3NVAxKM7:TR?=	M2jhUFI1KGh?	NUD5NJJlTE2VTx?=	NXfYTIpjUUN3ME2wMlA5OCEQvF2=	NUXzdpprRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyO\|Q{QTlpPkKyNlc1Ozl7PD;hQi=>
A-673	NFLTUGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn[4NVAh\|ryP	MXS5OkBp	MnHISG1UVw>?	MVHJR\|UxRTBwMEOyJO69VQ>?	M{DM[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNES4OVkyLz5{MUS0PFU6OTxxYU6=
TC-32	M3\1Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWLLZZRFOTBizszN	NHjTUWk6PiCq	MUnEUXNQ	M4TOSmlEPTB;MD6wN\|kh\|ryP	Mn;yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2NEi1PVEoRjJzNES4OVkyRC:jPh?=
TC-71	NXjuXYRUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIPIR2kyOCEQvF2=	MWq5OkBp	NF7UPXdFVVOR	NWDxOXpZUUN3ME2wMlExOiEQvF2=	M4DpVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNES4OVkyLz5{MUS0PFU6OTxxYU6=
SK-N-MC	MkftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NW\ndG41OTBizszN	M4LJWlk3KGh?	NXHjOFFrTE2VTx?=	NIPCTFVKSzVyPUCuNFczKM7:TR?=	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR2OEW5NUc,OjF2NEi1PVE9N2F-
CHLA-9	M4LFcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXft[GZmOTBizszN	NWH6b5AzQTZiaB?=	MX7EUXNQ	M4XCc2lEPTB;MD6wNVgh\|ryP	NUTUcYxXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OFg2QTFpPkKxOFQ5PTlzPD;hQi=>
CHLA-10	NXTWdW9kT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnLWNVAh\|ryP	NULWcXpHQTZiaB?=	NWX3TJpSTE2VTx?=	MYPJR\|UxRTBwME[wJO69VQ>?	M1LtTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNES4OVkyLz5{MUS0PFU6OTxxYU6=
CHLA-25	NWTPOHNwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH\yN4oyOCEQvF2=	NWHrVGtXQTZiaB?=	MX3EUXNQ	M4S1N2lEPTB;MD6xOlgh\|ryP	MoHDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2NEi1PVEoRjJzNES4OVkyRC:jPh?=
CHLA-32	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYmxNEDPxE1?	NGfpVW86PiCq	M{D2UWROW09?	NIPYRYZKSzVyPUCuNVM3KM7:TR?=	NUDUcG1QRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OFg2QTFpPkKxOFQ5PTlzPD;hQi=>
CHLA-56	NYC0PIFbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYmxNEDPxE1?	MkLFPVYhcA>?	NYH2VGpVTE2VTx?=	NWPsTVlCUUN3ME2xNEDPxE1?	NW\FPGRHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OFg2QTFpPkKxOFQ5PTlzPD;hQi=>
CHLA-258	M{XqRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlLpNVAh\|ryP	M1;I[\|k3KGh?	NFP5NndFVVOR	MoL6TWM2OD1yLkGzNkDPxE1?	M1fsVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNES4OVkyLz5{MUS0PFU6OTxxYU6=
COG-E-352	NU\Wc29DT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYixNEDPxE1?	MVG5OkBp	Mo\SSG1UVw>?	MnnkTWM2OD1yLkC0N{DPxE1?	Mln5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2NEi1PVEoRjJzNES4OVkyRC:jPh?=
CHLA-90	NVzsfotFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmexNVAh\|ryP	MYe5OkBp	NYGzNHBVTE2VTx?=	NFXHU\|VKSzVyPUCuNFYyKM7:TR?=	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR2OEW5NUc,OjF2NEi1PVE9N2F-
CHLA-119	NYjoR5ZjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Moi4NVAh\|ryP	MWK5OkBp	NXvBXpRtTE2VTx?=	NGH0c3BKSzVyPUCuNFIzKM7:TR?=	NYqzW5VkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OFg2QTFpPkKxOFQ5PTlzPD;hQi=>
CHLA-122	NGD0bVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX3aUGRiOTBizszN	M2TJXFk3KGh?	NFXUcWVFVVOR	NF:wO4lKSzVyPUCuNFE6KM7:TR?=	NX3PcHFxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OFg2QTFpPkKxOFQ5PTlzPD;hQi=>
CHLA-136	M4rwcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4P6TlExKM7:TR?=	M2rvOVk3KGh?	NGn5UXNFVVOR	Mn:1TWM2OD1yLkCzPUDPxE1?	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR2OEW5NUc,OjF2NEi1PVE9N2F-
CHLA-140	NXPCUngzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoKxNVAh\|ryP	NHL3UII6PiCq	MW\EUXNQ	MVzJR\|UxRTBwMEK2JO69VQ>?	M124cVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNES4OVkyLz5{MUS0PFU6OTxxYU6=
LA-N-6	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGnLNHkyOCEQvF2=	NVHwTpp3QTZiaB?=	NHzLVoZFVVOR	MVjJR\|UxRTBwMEW0JO69VQ>?	MoHJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2NEi1PVEoRjJzNES4OVkyRC:jPh?=
NB-1643	NF3zOJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYqxNEDPxE1?	Mn7SPVYhcA>?	M4rvVWROW09?	MVzJR\|UxRTBwMEO3JO69VQ>?	M{PUelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNES4OVkyLz5{MUS0PFU6OTxxYU6=
NB-EBc1	NYHTb49QT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2C0R\|ExKM7:TR?=	MmD6PVYhcA>?	Ml3BSG1UVw>?	NHTuZmVKSzVyPUCuNFUxKM7:TR?=	NXH4[JBjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OFg2QTFpPkKxOFQ5PTlzPD;hQi=>
SK-N-BE-1	MoC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV[xNEDPxE1?	NHjtVXY6PiCq	NYTaVXZzTE2VTx?=	NXzWXGxyUUN3ME2wMlAzQCEQvF2=	M{i3ZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNES4OVkyLz5{MUS0PFU6OTxxYU6=
SK-N-BE-2	NHTGT5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWni[oNCOTBizszN	NU[0RWtjQTZiaB?=	NVrTTmNlTE2VTx?=	MnnzTWM2OD1yLkCzOkDPxE1?	NEe4OIc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUS0PFU6OSd-MkG0OFg2QTF:L3G+
SMS-KAN	NEjjTYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYCxNEDPxE1?	NETFd\|Y6PiCq	MWHEUXNQ	Mo\lTWM2OD1yLkCzOEDPxE1?	M3HGflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNES4OVkyLz5{MUS0PFU6OTxxYU6=
SMS-KANR	NUD2VmVXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn:3NVAh\|ryP	NVzLVmFtQTZiaB?=	NXL1VW0yTE2VTx?=	MkXjTWM2OD1yLkCyOkDPxE1?	NGrNd3U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUS0PFU6OSd-MkG0OFg2QTF:L3G+
SMS-KCN	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlWzNVAh\|ryP	MnS1PVYhcA>?	MUPEUXNQ	MmPGTWM2OD1yLkCxPUDPxE1?	M2HGTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNES4OVkyLz5{MUS0PFU6OTxxYU6=
SMS-KCNR	Mn3DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVmxNEDPxE1?	NHrsSFA6PiCq	NEn0cGZFVVOR	MnXaTWM2OD1yLkCxNEDPxE1?	NIDmbZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUS0PFU6OSd-MkG0OFg2QTF:L3G+
SMS-LHN	NGXhRmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3nYdVExKM7:TR?=	M3PZSVk3KGh?	Mlv1SG1UVw>?	M3nqeGlEPTB;MD6wN\|Ih\|ryP	M2\hb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNES4OVkyLz5{MUS0PFU6OTxxYU6=
SMS-MSN	M{H4VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV:xNEDPxE1?	NVzuZo45QTZiaB?=	MU\EUXNQ	MoSwTWM2OD1yLkCyNkDPxE1?	NXHM[5BCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OFg2QTFpPkKxOFQ5PTlzPD;hQi=>
SMS-SAN	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NILSPYwyOCEQvF2=	MUG5OkBp	NXfYWmV4TE2VTx?=	NVLBPIY3UUN3ME2wMlAzOCEQvF2=	MlmyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2NEi1PVEoRjJzNES4OVkyRC:jPh?=
Granta-4	MVrDfZRwfG:6aXOgRZN{[Xl?	NYTrVIRQOTBizszN	MlLUO{Bl		MkDDTWM2OD1yLkC0NEDPxE1?	M{HM[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMkmxPFY4Lz5{MUK5NVg3PzxxYU6=
DB	NVj2T2NXS3m2b4TvfIlkKEG\|c3H5	M1W0W\|ExKM7:TR?=	MWi3JIQ>		M4j6[mlEPTB;MD6wOFIh\|ryP	M4DJSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMkmxPFY4Lz5{MUK5NVg3PzxxYU6=
RL	MXnDfZRwfG:6aXOgRZN{[Xl?	M2jWe\|ExKM7:TR?=	NVPIT4o6PyCm		NWDPb\|k6UUN3ME2wMlAyPSEQvF2=	NGLXfGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUK5NVg3Pyd-MkGyPVE5Pjd:L3G+
K562	NFvBNINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUWyfpd3OTBizszN	NH:3do86PiCq		MU\JR\|UxRTBwMEi3JO69VQ>?	MojTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFyOUG2N\|MoRjJzMEmxOlM{RC:jPh?=
LAMA-84	NYnpOFFGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWmxNEDPxE1?	NGDROow6PiCq		MW\JR\|UxRTBwMEW3JO69VQ>?	M3rnflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMEmxOlM{Lz5{MUC5NVY{OzxxYU6=
MM15	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXK0JO69VQ>?	MYK3NkBp	NHr4XZpFVVOR	NH;MZlFKSzVyPUCuNVMh\|ryP	NYHjd2poRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCzPFI5PDRpPkKwN\|gzQDR2PD;hQi=>
OPM1	MmjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml\COEDPxE1?	MVS3NkBp	NGHYTZlFVVOR	MnPhTWM2OD1yLkCzJO69VQ>?	NX63bXpIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCzPFI5PDRpPkKwN\|gzQDR2PD;hQi=>
RPM1	NFe3OmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYDzdY9wPCEQvF2=	NX6wVGF3PzJiaB?=	MXXEUXNQ	NGDBSYRKSzVyPUGwMlMzKM7:TR?=	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODN6Mki0OEc,OjB\|OEK4OFQ9N2F-
INA6	NEXkT\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYS0JO69VQ>?	NWn3fVJUPzJiaB?=	MVTEUXNQ	NHXLbXRKSzVyPUCuNFAzKM7:TR?=	NYHWTYVRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCzPFI5PDRpPkKwN\|gzQDR2PD;hQi=>
OPM2	NVuyNG5JT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVW0JO69VQ>?	NUnpdlN7PzJiaB?=	NHn1WJhFVVOR	MV\JR\|UxRTRwM{eg{txO	MnzSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB\|OEK4OFQoRjJyM{iyPFQ1RC:jPh?=
MM1R	NVXYc4xWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NILTPWc1KM7:TR?=	NHXKfYg4OiCq	NUHnWGM4TE2VTx?=	NVfIO\|dUUUN3ME2xMlY5KM7:TR?=	M{f5VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyM{iyPFQ1Lz5{MEO4Nlg1PDxxYU6=
DOX40	MnjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnfKOEDPxE1?	NYfQRnozPzJiaB?=	M3TY[WROW09?	NUnZZ4ozUUN3ME21MlQ5KM7:TR?=	MmH4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB\|OEK4OFQoRjJyM{iyPFQ1RC:jPh?=
LR5	NX7IXlh{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{SxOFQh\|ryP	M{\XNFczKGh?	MV3EUXNQ	MkPlTWM2OD1{LkWzJO69VQ>?	NWPBTJdRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCzPFI5PDRpPkKwN\|gzQDR2PD;hQi=>
U266	MoT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEHBdIo1KM7:TR?=	MkjmO\|IhcA>?	NEnOdpZFVVOR	MorDTWM2OD1zLkSzJO69VQ>?	MkXGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB\|OEK4OFQoRjJyM{iyPFQ1RC:jPh?=
RD	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2LzSlExKM7:TR?=	MXe5OkBp		NFvyWlVKSzVyPUCuNlI5KM7:TR?=	MmfHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzMEizN\|goRjJyMUC4N\|M5RC:jPh?=
Rh41	NGf6[49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV2xNEDPxE1?	NYXmeJllQTZiaB?=		Ml7MTWM2OD1yLkC5NEDPxE1?	M2rtblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUC4N\|M5Lz5{MEGwPFM{QDxxYU6=
Rh30	M4W0[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFH5dWEyOCEQvF2=	NFjteW86PiCq		MWfJR\|UxRTBwMkOwJO69VQ>?	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODFyOEOzPEc,OjBzMEizN\|g9N2F-
BT-12	NFrRUJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NY\OZlIxOTBizszN	NEXhb4E6PiCq		M1vIUWlEPTB;MD6wOlAh\|ryP	MmjaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzMEizN\|goRjJyMUC4N\|M5RC:jPh?=
CHLA-266	M3vHNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYHOb4RQOTBizszN	MWO5OkBp		M1PCfGlEPTB;MD6wO\|Ih\|ryP	MlLxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzMEizN\|goRjJyMUC4N\|M5RC:jPh?=
TC-71	NYWyRmtZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmnYNVAh\|ryP	NYTrdmJtQTZiaB?=		M3HUTWlEPTB;MD6xNFIh\|ryP	NH[4TXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEGwPFM{QCd-MkCxNFg{Ozh:L3G+
SJ-GBM2	NGfSOWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVrQeYU1OTBizszN	NVS1WJpJQTZiaB?=		NEDQSmJKSzVyPUCuNFUxKM7:TR?=	NHnEOYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEGwPFM{QCd-MkCxNFg{Ozh:L3G+
NALM-6	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3jZUFExKM7:TR?=	MV[5OkBp		MofrTWM2OD1yLkC2NkDPxE1?	M2qwVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUC4N\|M5Lz5{MEGwPFM{QDxxYU6=
COG-LL-317	Ml\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFS0cYcyOCEQvF2=	MXm5OkBp		NFXqUG1KSzVyPUCuNFQ4KM7:TR?=	MmT1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzMEizN\|goRjJyMUC4N\|M5RC:jPh?=
RS4-11	MnXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmnQNVAh\|ryP	NFPmOHY6PiCq		MVPJR\|UxRTBwMEG4JO69VQ>?	M{[zNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUC4N\|M5Lz5{MEGwPFM{QDxxYU6=
MOLT-4	MmfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MW[xNEDPxE1?	NIrPbWw6PiCq		MWHJR\|UxRTBwMEK2JO69VQ>?	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODFyOEOzPEc,OjBzMEizN\|g9N2F-
CCRF-CEM	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHTvbHYyOCEQvF2=	NULDN2FJQTZiaB?=		NVHTRZhmUUN3ME2wMlA6PCEQvF2=	Mn7nQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzMEizN\|goRjJyMUC4N\|M5RC:jPh?=
Kasumi-1	Mlu0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXz2b\|R{OTBizszN	MV25OkBp		NEL1RnZKSzVyPUCuNVA{KM7:TR?=	NIXlUHI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEGwPFM{QCd-MkCxNFg{Ozh:L3G+
Karpas-299	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NInzOo0yOCEQvF2=	MV[5OkBp		MVnJR\|UxRTBwMEO4JO69VQ>?	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODFyOEOzPEc,OjBzMEizN\|g9N2F-
Ramos-RA1	M3rjWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXPWTpQ3OTBizszN	MX:5OkBp		MlT5TWM2OD1yLkGyO{DPxE1?	MlPMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzMEizN\|goRjJyMUC4N\|M5RC:jPh?=
GSS	Mo\MRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MWO3NkBpenN?		NEXQWlRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFfTV{Bk\WyuczDh[pRmeiB5MjDodpMh[nliV2PUPEBie3OjeTygTWM2OCB;IECuNFM6KM7:TT6=	NXrGd3FYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2NlU3OTdpPkK1OlI2PjF5PD;hQi=>
LU99A	NFX3XGhCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M2W0XVczKGi{cx?=		MlT3RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCOVUm5RUBk\WyuczDh[pRmeiB5MjDodpMh[nliV2PUPEBie3OjeTygTWM2OCB;IECuNFYzKM7:TT6=	Mnz2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4MkW2NVcoRjJ3NkK1OlE4RC:jPh?=
HL60	Moj4RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NFG5VHo4OiCqcoO=		M13P[2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFy2NEBk\WyuczDh[pRmeiB5MjDodpMh[nliV2PUPEBie3OjeTygTWM2OCB;IECuNFc1KM7:TT6=	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ{NU[xO{c,OjV4MkW2NVc9N2F-
LC2/ad	M{jyVmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M4H5eVczKGi{cx?=		MmjvRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCOQ{KvZYQh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IGfTWFgh[XO\|YYmsJGlEPTBiPTCwMlA4PyEQvF2u	NUnMR4VnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2NlU3OTdpPkK1OlI2PjF5PD;hQi=>
MKN45	MmTuRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NH\IPII4OiCqcoO=		MnOzRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPS160OUBk\WyuczDh[pRmeiB5MjDodpMh[nliV2PUPEBie3OjeTygTWM2OCB;IECuNFk{KM7:TT6=	NYTsfHBGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2NlU3OTdpPkK1OlI2PjF5PD;hQi=>
HCT116	Ml;JRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NIrXZW04OiCqcoO=		MULBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEGxOkBk\WyuczDh[pRmeiB5MjDodpMh[nliV2PUPEBie3OjeTygTWM2OCB;IECuNFk2KM7:TT6=	NXPwS4oxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2NlU3OTdpPkK1OlI2PjF5PD;hQi=>
Lu116	NXG1WXVtSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MmKzO\|IhcHK\|		NUfCdpZjSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDMeVEyPiClZXzsd{Bi\nSncjC3NkBpenNiYomgW3NVQCCjc4PhfUwhUUN3MDC9JFAvODl5IN88UU4>	NHPqWZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[yOVYyPyd-MkW2NlU3OTd:L3G+
NCI-H358	MULBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M17iR\|czKGi{cx?=		M4nWV2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWg{PThiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JHdUXDhiYYPzZZktKEmFNUCgQUAxNjFizszNMi=>	M1q4NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkK1OlE4Lz5{NU[yOVYyPzxxYU6=
MIAPaCa2	MUnBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NYPo[XhGPzJiaILz		MWnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2LQWDhR4EzKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDXV3Q5KGG\|c3H5MEBKSzVyIE2gNE4yOyEQvF2u	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ{NU[xO{c,OjV4MkW2NVc9N2F-
PC14	NGS2fIdCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NHHkfJU4OiCqcoO=		MUPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFCFMUSgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KFeVVEigZZN{[XluIFnDOVAhRSByLkG3JO69VS5?	NFXZUJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[yOVYyPyd-MkW2NlU3OTd:L3G+
HT-29	NULqO5N3SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M1LOeFczKGi{cx?=		M1K0WmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSGStNlkh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IGfTWFgh[XO\|YYmsJGlEPTBiPTCwMlM{KM7:TT6=	Ml72QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4MkW2NVcoRjJ3NkK1OlE4RC:jPh?=
HCT15	MnX1RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MUe3NkBpenN?		Mn;WRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKQ2SxOUBk\WyuczDh[pRmeiB5MjDodpMh[nliV2PUPEBie3OjeTygTWM2OCB;IECuO\|Qh\|ryPLh?=	MlrXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4MkW2NVcoRjJ3NkK1OlE4RC:jPh?=
Sf9	NV:zUmg6TnWwY4Tpc44h[XO\|YYm=				NUn3fFR7S2:vcHX0bZRqfmViaX7obYJqfGmxbjDv[kBz\WOxbXLpcoFvfCCvb4Xz[UBifXKxcnGgb4lv[XOnIFGg[ZhxemW\|c3XkJIlvKGmwc3XjeEBU\jliY3XscJMhcW5icILld4Vv[2Vib3[gRXRRNCCNaTC9JFAvODByMzFOwG0v	NGny[W89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGwNVU3PCd-Mk[xNFE2PjR:L3G+
Sf9	NFLlb\|FHfW6ldHnvckBie3OjeR?=				MlPuTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDtc5V{\SCjdYLvdoEhc2mwYYPlJGEh\XiycnXzd4VlKGmwIHnud4VkfCCVZkmgZ4VtdHNidYPpcoch[mmxdHnuMWdNWlKDU1zHJIF{KHO3YoP0doF1\SCrbjDwdoV{\W6lZTDv[kBc\2GvbXGtN\|NRZUGWUDygTWM2OCB;IECuNFAyKM7:TT6=	NEC4XmY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGwNVU3PCd-Mk[xNFE2PjR:L3G+
HCT116	M2D4PWZ2dmO2aX;uJIF{e2G7				NYDicnlnUW6qaXLpeIlwdiCxZjDheZJwemFia3nuZZNmKEFiYYX0c5Bpd3OyaH;yfYxifGmxbjDheEBVOjh6IHnuJIh2dWGwIFjDWFEyPiClZXzsd{BjgSCrbX31co9ndHWxcnXzZ4Vv[2ViYX7hcJl{cXNuIFnDOVAhRSByLkCwO{DPxE1w	MnLuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzMEG1OlQoRjJ4MUCxOVY1RC:jPh?=
HCT116	M3PSZWN6fG:2b4jpZ4l1gSCjc4PhfS=>				MU\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBk\WyuIIDyc4xq\mW{YYTpc44h[nliQoLkWUBqdmOxcoDvdoF1cW:wIHHzd4F6NCCJSUWwJF0hOC5yMzFOwG0v	MnLIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzMEG1OlQoRjJ4MUCxOVY1RC:jPh?=
HCT116	MULGeY5kfGmxbjDhd5NigQ>?				MmjnTY5pcWKrdHnvckBw\iCjdYLvdoEhc2mwYYPlJGIhcW5iaIXtZY4hUEOWMUG2JINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiaHnzeI9v\SCKMzDwbI9{eGixconsZZRqd25iYomgbY1ufW6xZnz1c5Jme2OnbnPlJIFv[Wy7c3nzMEBKSzVyIE2gNU42KM7:TT6=	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjFyMUW2OEc,OjZzMEG1OlQ9N2F-
BL21 (DE3) Rosetta	M3PZSWZ2dmO2aX;uJIF{e2G7		MljNN\|AhdWmwcx?=		M3TlV2lvcGmkaYTpc44hd2ZiSHnzMZRi\2enZDDoeY1idiCDdYLvdoEhSSCtaX7hd4UhMDF{MjD0c{A1OCC{ZYPp[JVmeyliZYjwdoV{e2WmIHnuJGV{[2incnnjbIliKGOxbHmgRmwzOSBqRFWzLUBTd3OndIThJINmdGy\|IIXzbY5oKGKrb4Tpcplt[XSnZDDTWGszKHO3YoP0doF1\SCrbnP1ZoF1\WRiZn;yJFMxKG2rboOgZpkhUFSURjDhd5NigSxiSVO1NEA:KDBwMECwNFQh\|ryPLh?=	M37FPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5M{mxNVM{Lz5{N{O5NVE{OzxxYU6=
HeLa Kyoto	NUjHWohRTnWwY4Tpc44h[XO\|YYm=		NVyzWpVNOjBiaILz		MX;Jcohq[mm2aX;uJI9nKEG3cn;yZUBDKGurbnHz[UBqdiCqdX3hckBJ\UyjIFv5c5RwKGOnbHzzJIF{e2W\|c3XkJIF{KGWoZnXjeEBwdiCmaYP0doljfXSrb36gc4YheGi\|cHjvMYhqe3SxbnWgTFMhe2W{MUCgcIV3\WxiaX7jeYJifGWmIH\vdkAzOCCqcoOsJGlEPTBiPTCwMlAxOTVizszNMi=>	NH:0NFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{O5NVE{Oyd-MkezPVEyOzN:L3G+
HeLa Kyoto	NV;hZ3A5TnWwY4Tpc44h[XO\|YYm=		MYiyNEBpenN?		NXyzNYdHUW6qaXLpeIlwdiCxZjDBeZJwemFiQTDrbY5ie2ViYYX0c5Bpd3OyaH;yfYxifGmxbjDheEBVcHJ{OEigbY4hcHWvYX6gTIVN[SCNeX;0c{Bk\WyuczDpcoN2[mG2ZXSg[o9zKDJyIHjyd{whUUN3MDC9JFAvODB4NzFOwG0v	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzN7MUGzN{c,Ojd\|OUGxN\|M9N2F-
multiple myeloma	NGfhSXNHfW6ldHnvckBie3OjeR?=				MluxV5VxeHKnc4Ppc44hd2ZiY3XscEBucXSxc3nzJIlvKGi3bXHuJI12dHSrcHzlJI16\WyxbXGgZ4VtdHNuIFnDOVAhRSByLkCwN{DPxE1w	NV7uNpp1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5NVgxQTZpPkK4PVE5ODl4PD;hQi=>
Calu6	MoHvRY51cXS3bX;yJIF{e2G7	Mn3tNlAhdWdxa3e=	NWLQW\|MzOjFiZHH5dy=>		MlLNRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQ3HseVYh[2WubIOgfIVvd2e{YX\0[YQhcW5ibX;1d4Uh[XO\|ZYPz[YQh[XNidIXtc5Ih\3Kxd4ToJIlvcGmkaYTpc44h[XRiMkCgcYcwc2duIIDvJIJq\CCjZH3pcol{fGW{ZXSg[o9zKDJzIHThfZM>	M4HiNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUCxOVY1Lz5{NkGwNVU3PDxxYU6=
HeLa Kyoto	MXTGeY5kfGmxbjDhd5NigQ>?	M4DvSlAvOjVidV2=	M4HwUFIxKGi{cx?=		NF;KeWNKdmirYnn0bY9vKG:oIFH1do9z[SCDIHvpcoF{\SCub3PhcIl7[XSrb36gZZQhe3CrbnTs[UBucWO{b4T1ZpVt\XNiaX6gbJVu[W5iSHXMZUBMgW:2bzDj[YxteyCjdDCwMlI2KHWPIHnuZ5Vj[XSnZDDmc5IhOjBiaILz	NH7aRVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{O5NVE{Oyd-MkezPVEyOzN:L3G+
MDA-MB-231	NEHFV3NHfW6ldHnvckBie3OjeR?=	NYr6SVJbOSC3TR?=	NEjGTHc1QCCqcoO=		MkiwTY5lfWO2aX;uJI9nKGOqcn;tc5NwdWViYXzp[45u\W62IHTl[oVkfHNiaX6gbJVu[W5iTVTBMW1DNTJ\|MTDj[YxteyCjdDCxJJVOKGGodHXyJFQ5KGi{czDifUBFSVCLIIP0ZYlvcW6pIHLhd4VlKGmvbYXuc4ZtfW:{ZYPj[Y5k\SCjc4PhfS=>	MmPpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl\|NUixOFcoRjJ7M{W4NVQ4RC:jPh?=
MDA-MB-231	MmTNSpVv[3Srb36gZZN{[Xl?	M2j2TlEhfU1?	NH3VPY41QCCqcoO=		Ml\QTY5lfWO2aX;uJI9nKGGkZYLyZY51KHOyaX7kcIUh\m:{bXH0bY9vKHerdHigeJJqeG:uYYKgZY5lKHSndILhdI9t[XJib3PjeZJz\W6lZTDpckBpfW2jbjDNSGEuVUJvMkOxJINmdGy\|IHH0JFEhfU1iYX\0[ZIhPDhiaILzJIJ6KESDUFmgd5RicW6rbnegZoF{\WRiaX3teY5w\my3b4Lld4NmdmOnIHHzd4F6	MlLiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl\|NUixOFcoRjJ7M{W4NVQ4RC:jPh?=
MDA-MB-231	MXzGeY5kfGmxbjDhd5NigQ>?	M{K0c\|AvPSC3TR?=	NXrJTW91PDhiaILz		M2\jc2lvcGmkaYTpc44hd2ZiYXzwbIEufHWkdXzpckBqdiCqdX3hckBOTEFvTVKtNlMyKGOnbHzzJIF{e2W\|c3XkJIF{KGGkb3zpd4hu\W62IH;mJJJm\3WuYYKgcI9k[XSrb36gc4YheHKxdHXpckBifCByLkWgeW0h[W[2ZYKgOFghcHK\|IHL5JGRCWElic4ThbY5qdmdiYnHz[YQhcW2vdX7v[ox2d3Knc3PlcoNmKGG\|c3H5	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTN3OEG0O{c,Ojl\|NUixOFc9N2F-
MDA-MB-231	M1HZT2Z2dmO2aX;uJIF{e2G7	NVj1NmpZOC53IIXN	NIDUXY41QCCqcoO=		NVTQUJlLUW6qaXLpeIlwdiCxZjDBWXJMSSCrbjDoeY1idiCPRFGtUWIuOjNzIHPlcIx{KGG\|c3Xzd4VlKGG\|IHHic4xqe2ivZX70JI9nKHKnZ4XsZZIhdG:lYYTpc44hd2ZicILveIVqdiCjdDCwMlUhfU1iYX\0[ZIhPDhiaILzJIJ6KESDUFmgd5RicW6rbnegZoF{\WRiaX3teY5w\my3b4Lld4NmdmOnIHHzd4F6	M1TJZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7M{W4NVQ4Lz5{OUO1PFE1PzxxYU6=
TC32	NI\xdodyUFSVIHHzd4F6				MYXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhXEN\|MjDj[Yxtew>?	MlvRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Saos-2	NVj3UY9CeUiWUzDhd5NigQ>?				NWKzN4VxeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPhc5MuOiClZXzsdy=>	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-SH	M2m2dJFJXFNiYYPzZZk>				NVrSeoRreUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPLMW4uW0hiY3XscJM>	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
MG 63 (6-TG R)	MYHxTHRUKGG\|c3H5				MYHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVUdiNkOgLFYuXEdiUjmgZ4VtdHN?	NWPWZ2NjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB1643	MV;xTHRUKGG\|c3H5				NX24TXdSeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF7CNVY1OyClZXzsdy=>	NIr5TJk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
NB-EBc1	NFPJdJpyUFSVIHHzd4F6				NF3ue2FyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBPSi2HQnOxJINmdGy\|	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
MG 63 (6-TG R)	NWewXI54eUiWUzDhd5NigQ>?				MUfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDNS{A3OyBqNj3US{BTMSClZXzsdy=>	MlvhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
U-2 OS	M{WyXpFJXFNiYYPzZZk>				MV3xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDVMVIhV1NiY3XscJM>	MmnYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2	MkTSdWhVWyCjc4PhfS=>				MUjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucx?=	NE\IXoU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-MC	NYXrVlRueUiWUzDhd5NigQ>?				M3HN[5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMW1EKGOnbHzz	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
NB-EBc1	NUDVXI9KeUiWUzDhd5NigQ>?				Mn:xdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6ELVXCZ\|Eh[2WubIO=	NIDzfWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
LAN-5	M4ezZZFJXFNiYYPzZZk>				NWj1NnVleUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFzBUk02KGOnbHzz	MmHaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Rh18	MVvxTHRUKGG\|c3H5				NIX2WHFyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUnixPEBk\Wyucx?=	M4jGN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC	MXfxTHRUKGG\|c3H5				NUTUTYNEeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?=	NGnEdYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
TC32	NEO5b\|VyUFSVIHHzd4F6				NYHUTpl4eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhXEN\|MjDj[Yxtew>?	NIrJfow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Saos-2	NH3hO2lyUFSVIHHzd4F6				M3;jWJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHNid3NvMjDj[Yxtew>?	Mnf6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-AURKA(T288) / p-EIF4E(S209) / c-Myc; PubMed: 28073841 Clin Cancer Res Inhibition of AURKA with alisertib downregulated p-EIF4E (S209) and c-MYC protein levels as assayed by Western blotting. phospho-Aurora A / Aurora B; PubMed: 22863010 Cell MLN8237differentially inhibited phosphorylation of Aurora kinases. CMK cells were incubated with 0.1 µM paclitaxel for 18 hr, then DMSO or MLN8237 was added and incubated for 2 hr. The degree of phosphorylation of the Aurora kinases in each sample was determined by Western blot. H3S10P / H3K27me2 / H3K27me3 / H3K9me2 / H3AcK / H4K16Ac; PubMed: 29477140 Mol Cells THP-1 cells were treated with alisertib or DMSO for 48 h. The levels of histone modifications were detected by western blot analysis with the indicated antibodies. H3 was used as a loading control.	28073841 22863010 29477140
Growth inhibition assay	Cell viability; PubMed: 25632225 Drug Des Devel Ther PANC-1 and BxPC-3 cells were treated with ALS at concentrations ranging from 0.1 μM to 50 μM for 24 hours. The viability of PANC-1 and BxPC-3 cells determined by MTT assay. ALS, alisertib.	25632225
Immunofluorescence	acetylated α-tubulin / γ-tubulin; PubMed: 29401581 FASEB J Representative immunofluorescence (IF) image and graph in human PKD1-mutant WT9-7, WT9-12 cells or hTERT-RPE1 (RPE1) cells after 2 hours treatment with vehicle, ganetespib , or alisertib to inhibit AURKA, or combination of alisertib and ganetespib. acetylated α-tubulin (red); γ-tubulin (green); DAPI (blue). Scale bars, 5 μm. E-cadherin / β-catenin / vimentin / p-SMAD5; PubMed: 23334326 Oncogene Immunofluorescence analysis of CD24 (-/low) cells treated with1 μM MLN8237 for 48 and 72 h showing reversion of EMT. E-cadherin and p-SMAD5 were labeled in red, β-catenin and vimentin were labeled in green, and DNA was labeled in blue with Hoechst dye. Centrin-2 / tubulin; PubMed: 30899434 Oncotarget Following inhibition of Aurora A kinase activity with 100 nM alisertib, cells with two or excess centrosomes similarly exhibit disorganized mitotic spindles. Cells with extra centrosomes are efficiently clustered into bipolar spindles prior to anaphase onset while those with supernumerary centrosomes undergo multipolar mitoses. Centrin-2, a marker of centrioles is shown in green, tubulin in red, and chromatin in blue. AurA inhibitor: alisertib. phospho-Aurora A(T288); PubMed: 20382844 Blood MM1.S cells were treated with DMSO or MLN8237 (0.5μM) for 24 hours and then stained with anti-phospho (Thr288)-Aurora-A kinase antibody (red), αtubulin (green), and DNA (blue). Overlapping localization is shown in the merged images. Arrow indicates Aurora-A autophosphorylation on Thr288 in the centrosome (original magnification ×40). Magnified single mitotic cell image is shown in the right panel.	29401581 23334326 30899434 20382844

体内研究

MLN8237口服处理，显著降低肿瘤负担，按15 mg/kg 和30 mg/kg剂量处理肿瘤生长抑制率(TGI) 分别为42%和80%,且与对照组相比，延迟小鼠寿命。^[2] MLN8237 (30 mg/kg) 与Cisplatin (2 mg/kg) 联用作用于FLO-1移植瘤，与单独用药相比，抗癌活性增强，伴随着Ki-67表达受抑制，细胞核p73蛋白和cleaved caspase 3表达增强。^[3]

激酶实验：^[1]	- 合并 Aurora A放射性闪光板酶实验: 进行Aurora A放射性闪光板酶实验，测定体外MLN8237抑制程度。在Sf9细胞中表达重组Aurora A，然后使用GST亲和层析进行纯化。Aurora A 肽底物与生物素联合形成生物素-GLRRASLG。在50 mM Hepes (pH 7.5), 10 mM MgCl₂, 5 mM DTT, 0.05% Tween-20, 2 μM 肽底物, 3.3 μCi/mL [γ-³³ P]ATP 2 μM, 和浓度不断增高的MLN8237 的混合物中进行Aurora A激酶 (5 nM)实验。
细胞实验：^[2]	- 合并 Cell lines: MM1.S, MM.1R, LR5, RPMI 8226, DOX40, OPM1, OPM2, INA6, 和U266 Concentrations: 溶于DMSO,终浓度为~10 μM Incubation Time: 24, 48, 和72小时 Method: 使用不同浓度MLN8237处理细胞24, 48,和72小时。通过MTT实验测定细胞活力，通过测定 3[³H]-胸甘渗透而测定细胞增殖。为了分析细胞周期，使用70%乙醇在-20^oC下使细胞通透，然后与50 μg/mL PI 和20 单位/mL RNase-A温育。通过流式细胞仪使用 BDFACS-Canto II和FlowJo软件分析DNA含量。为了测定凋亡和衰老，使用异硫氰酸荧光素-annexin V和PI对细胞进行染色。通过流式细胞仪使用 BDFACS-Canto II和FlowJo软件测定凋亡细胞。 (Only for Reference)
动物实验：^[2]	- 合并 Animal Models: 皮下接种 MM1.S 细胞的SCID鼠 Dosages: ~30 mg/kg/day Administration: 口服处理 (Only for Reference)

参考文献

溶解度 (25°C)

体外	DMSO	27 mg/mL (52.03 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5%DMSO+30% PEG300+5%Tween-80+ddH2O	6mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Alisertib (MLN8237) SDF

分子量	518.92
化学式	C₂₇H₂₀ClFN₄O₄
CAS号	1028486-01-2
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2020-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04479306	Recruiting	Drug: Alisertib\|Drug: Osimertinib\|Drug: Sapanisertib	EGFR T790M Mutation Positive Non-Small Cell Lung Carcinoma\|Recurrent Lung Non-Small Cell Carcinoma\|Stage IIIB Lung Cancer AJCC v8\|Stage IV Lung Cancer AJCC v8\|Stage IVA Lung Cancer AJCC v8\|Stage IVB Lung Cancer AJCC v8	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	June 18 2020	Phase 1
NCT02812056	Withdrawn	Drug: Alisertib\|Drug: TAK-228	Malignant Neoplasms of Digestive Organs\|Malignant Neoplasms of Female Genital Organs\|Malignant Neoplasms of Lip Oral Cavity and Pharynx\|Malignant Neoplasms of Male Genital Organs	M.D. Anderson Cancer Center\|Millennium Pharmaceuticals Inc.	September 2016	Phase 1
NCT02719691	Active not recruiting	Drug: Alisertib\|Drug: MLN0128	Metastatic Breast Cancer\|Solid Tumors	University of Colorado Denver	May 13 2016	Phase 1
NCT02367352	Terminated	Drug: Alisertib\|Drug: Paclitaxel	Advanced Solid Tumors\|Ovarian Cancer\|Small Cell Lung Cancer	Millennium Pharmaceuticals Inc.\|Takeda	March 19 2015	Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
What is the suggested formulation of this compound for mouse injection(i.p.)?
回答：
It can be dissolved in 6% DMSO/50% PEG 300/5% Tween 80/ddH2O at 10 mg/ml as a clear solution.

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

泛Aurora Kinase抑制剂

Danusertib (PHA-739358) : Pan-Aurora kinase inhibitor, Aurora A/B/C, IC50=13 nM/79 nM/61 nM.
泛Aurora Kinase抑制剂

SNS-314 Mesylate : Pan-Aurora kinase inhibitor, Aurora A/B/C, IC50=9 nM/31 nM/3 nM.
活性最高的Aurora Kinase抑制剂

MK-5108 (VX-689) : Aurora A, IC50=0.064 nM.
用于临床的Aurora Kinase抑制剂

VX-680 (Tozasertib, MK-0457) : Phase II for Advanced Non-Small Cell Lung Cancer (NSCLC).
经典的Aurora Kinase抑制剂

Hesperadin : Potently inhibits Aurora B with IC50 of 250 nM.

研究领域

产品类型

定制您的化合物库

Alisertib (MLN8237)

客户使用Selleck生产的Alisertib (MLN8237)发表文献235篇：

产品安全说明书

Aurora Kinase抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Alisertib (MLN8237) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2020-01-06)

技术支持

常见问题及建议解决方法

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

相关Aurora Kinase产品